Cancer Center > ResearchNews
John P  Murtha Cancer Center Logo
Research & Funding News

Future funding opportunities that develop will be posted here. For more information you may contact Reisha Maharaj, Program Coordinator, Murtha Cancer Center at reisha.t.maharaj.ctr@mail.mil.

Funding ​Opportunity Announcement
The Murtha Cancer Center is now requesting for applications (RFA) for FY 17 Funding. For detailed information, click the link below. 

MCC RFA FY 17 - Collaborative Clinical Translational Sciences Research Program

Recipients of the Murtha Cancer Center grants in collaborative translational cancer research.

Five proposals from collaborative teams of Murtha Cancer Center members were awarded research grants in March 2014 of $300,000 from the Murtha Cancer Center based on top scores from an external peer review and programmatic focus. The grant recipients include:
  1. Dr. Thomas Darling with co-investigators Drs. A. Jarell, J. Marquart, J. Meyerle. “The pro-tumorigenic microenvironment in melanoma”.

    This study will examine the role of cancer associated fibroblasts (CAFs) in melanoma progression and as an independent prognostic factor for melanoma. The studies will form the groundwork for future approaches using CAFs for melanoma prognosis and targeting CAFs to augment existing therapies for melanoma.

  2. Dr. Brian Schaefer with co-investigators Drs. C. Carter, C. Dalgard and T. Summers. “Induction of an immunosuppressive microenvironment during lung cancer tumorigenesis”.

    The contribution of myeloid lineage cells, including macrophages and myeloid-derived suppressor cells, to play a role in tumor-associated immunosuppression in early lung tumors and promote changes in the phenotype of tumor-proximal myeloid cells thus establishing an immunosuppressive microenvironment will be examined. The studies will be conducted using a rodent model of lung cancer and analysis of human lung tumors.

  3. Dr. Andrew Snow with co-investigator Dr. H. Hu. “Molecular mechanisms linking NF-KB to tumor progression in aggressive breast cancer”.

    This research will determine if amplified signaling through the CARD10-BCL10-M ALT1 scaffolding complex drives spontaneous NF-κB activation in certain breast cancer subtypes and cancer stem cells, and correlates with more aggressive tumors and poorer clinical outcomes.

  4. Dr. Meera Srivastava with co-investigators Drs. M. Hueman, and H. Hu. “Race specific molecular determinants of recurrence in breast cancer subtypes”.

    By detecting proteins released by breast cancer cells into the circulation this research will create a set of diagnostic and prognostic biomarkers that can predict recurrence and metastasis in breast cancer. The biomarkers will be employed to identify race and subtype specific tumor biosignatures that can accurately predict recurrent and metastatic disease.

  5. Dr. Viqar Syed with Drs. G. Maxwell, C. Zahn, C. Hamilton. “Role of Nestin in endometrial cancer invasion and metastasis”.

    This research will determine if elevated levels of Nestin are associated with endometrial tumor progression and metastasis and if downregulation of Nestin with progesterone will halt metastatic colonization and have a clinical benefit in this disease.


Cancer Center at WRB
Bldg 19 (America)
8901 Wisconsin Avenue
Bethesda, MD 20889-5600

Hours of Operation:
Monday thru Friday
0730 - 1600